Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 55

Sort by

Sort Order Select

Journal Articles

Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma

Doris K. Hansen, Lauren C. Peres, Danai Dima, Alicia Richards, Leyla O. Shune, Aimaz Afrough, Shonali Midha, Binod Dhakal, Mehmet H. Kocoglu, Shebli Atrash, Chris Ferreri, Omar Castaneda, James A Davis, Evguenia Ouchveridze, Joseph P. McGuirk, Charlotte B Wagner, Radhika Bansal, Patrick Costello, Kinaya Smith, Alex Lieberman-Cribbin, Gabriel De Avila, Sneha Purvey, Hitomi Hosoya, Lekha Mikkilineni, Laura B. Oswald, Gurbakhash Kaur, Oren Pasvolsky, Mahmoud R. Gaballa, Megan M Herr, Peter A. Forsberg, Murali Janakiram, Myo Htut, Sireesha Asoori, Nilesh Kalariya, Hamza Hashmi, Ran Reshef, Douglas W Sborov, Omar Nadeem, Faiz Anwer, Jack Khouri, Shahzad Raza, Djordje Atanackovic, Melissa Alsina, Ciara Louise Freeman, Frederick L. Locke, Peter M. Voorhees, Larry D Anderson, Jr., Shambavi Richard, Thomas Martin, Yi Lin, Krina K. Patel, Surbhi Sidana

Blood (2024) 144 (Supplement 1): 936.

https://doi.org/10.1182/blood-2024-194390

Published: 2024

Journal Articles

Outcomes of Elderly Patients with Relapsed Refractory Multiple Myeloma (RRMM) Treated with Teclistamab: A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium

Blood (2024) 144 (Supplement 1): 934.

https://doi.org/10.1182/blood-2024-205989

Published: 2024

Journal Articles

Prognostic Significance of TP53 Mutations in Lymphoplasmacytic Lymphoma

Anath Lionel, Sherif Seif, Xiaowen Sun, Lei Feng, Lorenzo Gensini, Bria Gabriel, Lauren S. Lewis, Hima Bansal, Melody R. Becnel, Mahmoud R. Gaballa, Hans C. Lee, Oren Pasvolsky, Krina K. Patel, J Christine Ye, Keyur P. Patel, Donna M. Weber, Robert Z. Orlowski, Sheeba K. Thomas

Blood (2024) 144 (Supplement 1): 3024.

https://doi.org/10.1182/blood-2024-211193

Published: 2024

Journal Articles

Characterization of Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma Using Single Cell Transcriptomic Analysis

Minghao Dang, Sherif Seif, Maria Jose Acevedo-Calado, Linghua Wang, Bria Gabriel, Lauren S. Lewis, Lorenzo Gensini, Hima Bansal, Melody R. Becnel, Mahmoud R. Gaballa, Hans C. Lee, Oren Pasvolsky, Krina K. Patel, Donna M. Weber, J Christine Ye, Robert Z. Orlowski, Sheeba K. Thomas

Blood (2024) 144 (Supplement 1): 1584.

https://doi.org/10.1182/blood-2024-208915

Published: 2024

Journal Articles

Multi-Omic Single-Cell Characterization of Paired and Serial Samples in Responding and Non-Responding Patients Receiving BCMA Bispecific Antibody Therapy for Multiple Myeloma

Minghao Dang, Hans C. Lee, Hima Bansal, Maria Jose Acevedo-Calado, Li Qin, Wei Tan, Luz Yurany Moreno Rueda, David Berrios, Oren Pasvolsky, Mahmoud R. Gaballa, Melody R. Becnel, J Christine Ye, Krina K. Patel, Pei Lin, Sheeba K. Thomas, Donna M. Weber, Linghua Wang, Robert Z. Orlowski

Blood (2024) 144 (Supplement 1): 3272.

https://doi.org/10.1182/blood-2024-210080

Published: 2024

Journal Articles

Talquetamab Bridging: Paving the Way to B-Cell Maturation Antigen (BCMA) CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM)

Blood (2024) 144 (Supplement 1): 931.

https://doi.org/10.1182/blood-2024-202017

Published: 2024

Journal Articles

Outcomes of Teclistamab (Tec) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Prior Exposure to BCMA-Directed Therapy (BCMA-DT): A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium

Blood (2024) 144 (Supplement 1): 897.

https://doi.org/10.1182/blood-2024-203409

Published: 2024

Journal Articles

Pre-Apheresis Prediction of Toxicity and Response in Patients Receiving BCMA-Directed CAR-T for Relapsed/Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 895.

https://doi.org/10.1182/blood-2024-208376

Published: 2024

Journal Articles

Unveiling Clinical Potential: Exploring Cytogenomic Aberrations through Optical Genomic Mapping in Multiple Myeloma

J Christine Ye, Guilin Tang, Oren Pasvolsky, Melody R. Becnel, Mahmoud R. Gaballa, Krina K. Patel, Hans C. Lee, Sheeba K. Thomas, Donna M. Weber, Pei Lin, Robert Z. Orlowski

Blood (2024) 144 (Supplement 1): 1971.

https://doi.org/10.1182/blood-2024-212346

Published: 2024

Journal Articles

Functional Geriatric Assessment Tests Predict Toxicity Rates in Functional High Risk Myeloma Patients Treated with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone in a Prospective Clinical Trial

Blood (2024) 144 (Supplement 1): 6965.

https://doi.org/10.1182/blood-2024-202392

Published: 2024

Journal Articles

Impact of Ethnicity on Long Term Outcomes of High-Dose Chemotherapy and Upfront Autologous Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma

Blood (2024) 144 (Supplement 1): 5154.

https://doi.org/10.1182/blood-2024-203824

Published: 2024

Journal Articles

Post-CAR-T Driving Restrictions after Week 4 Appear Unnecessary: Data from the United States Myeloma Immunotherapy Consortium

Blood (2024) 144 (Supplement 1): 3765.

https://doi.org/10.1182/blood-2024-199609

Published: 2024

Journal Articles

Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel

Lauren C. Peres, Alicia Richards, Surbhi Sidana, Laura B. Oswald, Danai Dima, Aimaz Afrough, Leyla O. Shune, Shonali Midha, Omar Castaneda, Christopher Ferreri, James A Davis, Oren Pasvolsky, Christen M. Dillard, Megan M Herr, Mehmet H. Kocoglu, Shebli Atrash, Brandon Blue, Evguenia Ouchveridze, Joseph P. McGuirk, Charlotte B Wagner, Radhika Bansal, Patrick Costello, Kinaya Smith, Alex Lieberman-Cribbin, Gabriel De Avila, Sneha Purvey, Hitomi Hosoya, Lekha Mikkilineni, Gurbakhash Kaur, Mahmoud R. Gaballa, Peter A. Forsberg, Ciara Louise Freeman, Murali Janakiram, Myo Htut, Sireesha Asoori, Nilesh Kalariya, Djordje Atanackovic, Binod Dhakal, Jack Khouri, Shahzad Raza, Ran Reshef, Melissa Alsina, Frederick L. Locke, Omar Nadeem, Faiz Anwer, Larry D Anderson, Jr., Shambavi Richard, Yi Lin, Thomas Martin, Peter M. Voorhees, Krina K. Patel, Doris K. Hansen, Douglas W Sborov

Blood (2024) 144 (Supplement 1): 3785.

https://doi.org/10.1182/blood-2024-210078

Published: 2024

Journal Articles

Predictors and Characterization of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) in Patients with Multiple Myeloma Receiving Teclistamab

Blood (2024) 144 (Supplement 1): 3337.

https://doi.org/10.1182/blood-2024-206357

Published: 2024

Journal Articles

Clearance of Circulating Multiple Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 4687.

https://doi.org/10.1182/blood-2024-209181

Published: 2024

Journal Articles

Conditioning with Busulfan + Melphalan Versus Single-Agent Melphalan for Patients with Multiple Myeloma Receiving Autologous Stem Cell Transplantation: A Propensity Score-Matched Analysis

Blood (2024) 144 (Supplement 1): 7019.

https://doi.org/10.1182/blood-2024-203529

Published: 2024

Journal Articles

Second Line Treatment in Patients with Multiple Myeloma Progressing after Bortezomib, Lenalidomide, Dexamethasone Induction, Autologous Transplant and Lenalidomide Maintenance

Blood (2024) 144 (Supplement 1): 7018.

https://doi.org/10.1182/blood-2024-203404

Published: 2024

Journal Articles

Outcomes of Patients with Multiple Myeloma with Deletion 1p Following Autologous Stem Cell Transplant

Blood (2024) 144 (Supplement 1): 3344.

https://doi.org/10.1182/blood-2024-203700

Published: 2024

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation in Adolescents and Young Adults with Acute Lymphoblastic Leukemia - Retrospective Dual-Center Study

Blood (2023) 142 (Supplement 1): 4979.

https://doi.org/10.1182/blood-2023-179962

Published: 2023

Journal Articles

Patient Characteristics and Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Blood (2023) 142 (Supplement 1): 4988.

https://doi.org/10.1182/blood-2023-181031

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma

Outcomes of Elderly Patients with Relapsed Refractory Multiple Myeloma (RRMM) Treated with Teclistamab: A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium

Prognostic Significance of TP53 Mutations in Lymphoplasmacytic Lymphoma

Characterization of Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma Using Single Cell Transcriptomic Analysis

Multi-Omic Single-Cell Characterization of Paired and Serial Samples in Responding and Non-Responding Patients Receiving BCMA Bispecific Antibody Therapy for Multiple Myeloma

Talquetamab Bridging: Paving the Way to B-Cell Maturation Antigen (BCMA) CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM)

Outcomes of Teclistamab (Tec) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Prior Exposure to BCMA-Directed Therapy (BCMA-DT): A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium

Pre-Apheresis Prediction of Toxicity and Response in Patients Receiving BCMA-Directed CAR-T for Relapsed/Refractory Multiple Myeloma

Unveiling Clinical Potential: Exploring Cytogenomic Aberrations through Optical Genomic Mapping in Multiple Myeloma

Functional Geriatric Assessment Tests Predict Toxicity Rates in Functional High Risk Myeloma Patients Treated with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone in a Prospective Clinical Trial

Impact of Ethnicity on Long Term Outcomes of High-Dose Chemotherapy and Upfront Autologous Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma

Post-CAR-T Driving Restrictions after Week 4 Appear Unnecessary: Data from the United States Myeloma Immunotherapy Consortium

Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel

Predictors and Characterization of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) in Patients with Multiple Myeloma Receiving Teclistamab

Clearance of Circulating Multiple Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

Conditioning with Busulfan + Melphalan Versus Single-Agent Melphalan for Patients with Multiple Myeloma Receiving Autologous Stem Cell Transplantation: A Propensity Score-Matched Analysis

Second Line Treatment in Patients with Multiple Myeloma Progressing after Bortezomib, Lenalidomide, Dexamethasone Induction, Autologous Transplant and Lenalidomide Maintenance

Outcomes of Patients with Multiple Myeloma with Deletion 1p Following Autologous Stem Cell Transplant

Allogeneic Hematopoietic Stem Cell Transplantation in Adolescents and Young Adults with Acute Lymphoblastic Leukemia - Retrospective Dual-Center Study

Patient Characteristics and Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only